Acute myeloid leukemia (AML) is the most common acute leukemia in adults. The
pathophysiology of this disease is just beginning to be understood at the cellular and …

The outlook for patients with acute myeloid leukaemia has improved in the past 30 years.
Unlike other cancers, much of this progress is attributable to refinement of supportive …

Tumour heterogeneity remains a major challenge in cancer therapy owing to the different
susceptibility of cells to chemotherapy within a solid tumour. Cancer stem-like cells (CSCs) …

Summary N 6-Methyladenosine (m 6 A) represents the most prevalent internal modification
in mammalian mRNAs. Despite its functional importance in various fundamental …

TP53 is the most frequently mutated gene in cancer, yet these mutations remain
therapeutically non-actionable. Major challenges in drugging p53 mutations include …

Background All-trans retinoic acid (ATRA) with chemotherapy is the standard of care for
acute promyelocytic leukemia (APL), resulting in cure rates exceeding 80%. Pilot studies of …

Background Acute promyelocytic leukaemia is a chemotherapy-sensitive subgroup of acute
myeloid leukaemia characterised by the presence of the PML–RARA fusion transcript. The …

Retinoic acid (RA), the major bioactive metabolite of retinol or vitamin A, induces a spectrum
of pleiotropic effects in cell growth and differentiation that are relevant for embryonic …

The combination of all-trans-retinoic acid (ATRA) plus arsenic trioxide (ATO) has been
shown to be superior to ATRA plus chemotherapy in the treatment of standard-risk patients …

Arsenic, an ancient drug used in traditional Chinese medicine, has attracted worldwide
interest because it shows substantial anticancer activity in patients with acute promyelocytic …